Scholarlink

<p>To develop and validate prognostic nomograms for overall (OS) and progression-free survival (PFS) in gastroesophageal junction (GEJ) carcinoma to enable risk-stratified clinical decision-making. In this retrospective study of 618 patients, prognostic factors were selected using LASSO regression. Nomograms were constructed and validated by assessing discrimination (C-index, time-dependent ROC curves), calibration, and clinical utility (decision curve analysis). Patients were stratified into high- and low-risk groups based on nomogram-derived scores. The OS nomogram incorporated serum CD3 + CD8+ cells, mismatch repair status, metastatic lymph node count, and maximum tumor diameter. It demonstrated superior discriminative performance compared with the AJCC 9th edition staging system (C-index 0.716, 95% CI 0.679–0.752 vs. 0.683, 95% CI 0.646–0.721). The PFS nomogram included CD45 + CD3+CD19 + cells, CD3 + CD8+ cells, carcinoembryonic antigen, metastatic lymph nodes, and tumor diameter, also outperforming AJCC staging (C-index 0.709, 95% CI 0.676–0.743 vs. 0.647, 95% CI 0.610–0.684). Both models showed excellent calibration. Decision curve analysis confirmed their clinical utility across risk thresholds, with significant survival differences between risk groups (log-rank test, <i>p</i> &lt; 0.001). Restricted cubic spline analysis revealed nonlinear associations between key immune cell levels (CD45 + CD3+ and CD3 + CD8+) and survival outcomes (all <i>p</i> &lt; 0.05). This study establishes the first clinically validated risk-stratification model for GEJ carcinoma. The nomograms precisely identify low-risk patients who may avoid unnecessary adjuvant therapy and high-risk patients likely to benefit from treatment intensification, thereby enhancing personalized management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Integrating CD45 + CD3+ and CD3 + CD8+ T-cell markers into nomograms for predicting survival in gastroesophageal junction carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月1日

查看全文
  • Yubao Song,
  • Zhixiang Wang,
  • Jinfeng Ma,
  • Yifan Li,
  • Runping Su

摘要

To develop and validate prognostic nomograms for overall (OS) and progression-free survival (PFS) in gastroesophageal junction (GEJ) carcinoma to enable risk-stratified clinical decision-making. In this retrospective study of 618 patients, prognostic factors were selected using LASSO regression. Nomograms were constructed and validated by assessing discrimination (C-index, time-dependent ROC curves), calibration, and clinical utility (decision curve analysis). Patients were stratified into high- and low-risk groups based on nomogram-derived scores. The OS nomogram incorporated serum CD3 + CD8+ cells, mismatch repair status, metastatic lymph node count, and maximum tumor diameter. It demonstrated superior discriminative performance compared with the AJCC 9th edition staging system (C-index 0.716, 95% CI 0.679–0.752 vs. 0.683, 95% CI 0.646–0.721). The PFS nomogram included CD45 + CD3+CD19 + cells, CD3 + CD8+ cells, carcinoembryonic antigen, metastatic lymph nodes, and tumor diameter, also outperforming AJCC staging (C-index 0.709, 95% CI 0.676–0.743 vs. 0.647, 95% CI 0.610–0.684). Both models showed excellent calibration. Decision curve analysis confirmed their clinical utility across risk thresholds, with significant survival differences between risk groups (log-rank test, p < 0.001). Restricted cubic spline analysis revealed nonlinear associations between key immune cell levels (CD45 + CD3+ and CD3 + CD8+) and survival outcomes (all p < 0.05). This study establishes the first clinically validated risk-stratification model for GEJ carcinoma. The nomograms precisely identify low-risk patients who may avoid unnecessary adjuvant therapy and high-risk patients likely to benefit from treatment intensification, thereby enhancing personalized management.